BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

22 نوفمبر 2024 08:16:40 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Proposed Public Offering

21 نوفمبر 2024 16:47:12 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Third Quarter 2024 Financial Results

14 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s Dementia

12 نوفمبر 2024 07:00:01 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

08 نوفمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at ThinkEquity Conference

29 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

15 أكتوبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

19 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

05 سبتمبر 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth Conference

07 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2024 Financial Results

06 أغسطس 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024

30 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film

16 يوليو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Positive Topline Results from Post-Marketing Requirement Study Evaluating PRN Treatment of IGALMI™ (dexmedetomidine) Sublingual Film for Agitation Associated with Bipolar Disorders or Schizophrenia

25 يونيو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference

28 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

21 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2024 Financial Results

09 مايو 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024

25 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting

24 أبريل 2024 10:30:24 بحسب Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

22 أبريل 2024 07:00:00 بحسب Nasdaq GlobeNewswire